Stabilized trimers of the HIV-1 envelope glycoprotein Env are capable of inducing a potent and sustained broadly neutralizing antibody response in laboratory animals and therefore are attractive targets for anti-HIV vaccine development. In this work, a stable producer of the trimer Env recombinant form CRF63_02A6 of HIV-1 was derived from the CHO-K1 cell line. Using immunochemical assays, the trimers synthesized in CHO-K1 cells were shown to be recognized by both monoclonal broadly neutralizing antibodies and sera from HIV-positive patients. The resulting trimers of the recombinant form CRF63_02A6 of HIV-1 can be used both for structural studies and as a candidate vaccine immunogen against HIV-1.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2019 — 2018 data. Stockholm, 2019.
Medina-Ramírez M, Sanders RW, Sattentau QJ. Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. Curr. Opin. HIV AIDS. 2017;12(3):241-249. https://doi.org/10.1097/COH.0000000000000363
Derking R, Sanders RW. Structure-guided envelope trimer design in HIV-1 vaccine development: a narrative review. J. Int. AIDS Soc. 2021;24 Suppl 7(Suppl 7):e25797. https://doi.org/10.1002/jia2.25797
Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Peña AT, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, van Gils MJ, King CR, Wilson IA, Ward AB, Klasse PJ, Moore JP. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 2013;9(9):e1003618. https://doi.org/10.1371/journal.ppat.1003618
Pugach P, Ozorowski G, Cupo A, Ringe R, Yasmeen A, de Val N, Derking R, Kim HJ, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, Julien JP, Burton DR, Wilson IA, Sanders RW, Klasse PJ, Ward AB, Moore JP. A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. J. Virol. 2015;89(6):3380-3395. https://doi.org/10.1128/JVI.03473-14
Tumba NL, Owen GR, Killick MA, Papathanasopoulos MA. Immunization with HIV-1 trimeric SOSIP.664 BG505 or founder virus C (FVCEnv) covalently complexed to two-domain CD4S60C elicits cross-clade neutralizing antibodies in New Zealand white rabbits. Vaccine X. 2022;12:100222. https://doi.org/10.1016/j.jvacx.2022.100222
Wang Q, Ma B, Liang Q, Zhu A, Wang H, Fu L, Han X, Shi X, Xiang Y, Shang H, Zhang L. Stabilized diverse HIV-1 envelope trimers for vaccine design. Emerg. Microbes. Infect. 2020;9(1):775-786. https://doi.org/10.1080/22221751.2020.1745093
Houser KV, Gaudinski MR, Happe M, Narpala S, Verardi R, Sarfo EK, Corrigan AR, Wu R, Rothwell RS, Novik L, Hendel CS, Gordon IJ, Berkowitz NM, Cartagena CT, Widge AT, Coates EE, Strom L, Hickman S, Conan-Cibotti M, Vazquez S, Trofymenko O, Plummer S, Stein J, Case CL, Nason M, Biju A, Parchment DK, Changela A, Cheng C, Duan H, Geng H, Teng IT, Zhou T, O’Connell S, Barry C, Carlton K, Gall JG, Flach B, Doria-Rose NA, Graham BS, Koup RA, McDermott AB, Mascola JR, Kwong PD, Ledgerwood JE; VRC 018 Study Team. Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. EClinicalMedicine. 2022;48:101477. https://doi.org/10.1016/j.eclinm.2022.101477
Lapovok IA, Lopatukhin AE, Kireev DE, Kazennova EV, Lebedev AV, Bobkova MR, Kolomeets AN, Turbina GI, Shipulin GA, Ladnaya NN, Pokrovsky VV. Molecular epidemiological analysis of HIV-1 variants circulating in Russia in 1987-2015. Ter. Arkh. 2017;89(11):44-49. Russian. https://doi.org/10.17116/terarkh2017891144-49
Kuznetsova AI, Munchak IM, Lebedev AV, Tumanov AS, Kim KV, Antonova AA, Ozhmegova EN, Pronin AY, Drobyshevskaya EV, Kazennova EV, Bobkova MR. Genetic diversity of capsid protein (p24) in human immunodeficiency virus type-1 (HIV-1) variants circulating in the Russian Federation. Vopr. Virusol. 2023;68(1):66-78. https://doi.org/10.36233/0507-4088-161
Maksimenko LV, Totmenin AV, Gashnikova MP, Astakhova EM, Skudarnov SE, Ostapova TS, Yaschenko SV, Meshkov IO, Bocharov EF, Maksyutov RA, Gashnikova NM. Genetic Diversity of HIV-1 in Krasnoyarsk Krai: Area with High Levels of HIV-1 Recombination in Russia. Biomed. Res. Int. 2020;2020:9057541. https://doi.org/10.1155/2020/9057541
Rudometova NB, Shcherbakova NS, Shcherbakov DN, Mishenova EV, Delgado E, Ilyichev AA, Karpenko LI, Thomson MM. Genetic Diversity and Drug Resistance Mutations in Reverse Transcriptase and Protease Genes of HIV-1 Isolates from Southwestern Siberia. AIDS Res. Hum. Retroviruses. 2021;37(9):716-723. https://doi.org/10.1089/AID.2020.0225
Rudometova NB, Shcherbakova NS, Shcherbakov DN, Taranov OS, Zaitsev BN, Karpenko LI. Construction and Characterization of HIV-1 env-Pseudoviruses of the Recombinant Form CRF63_02A and Subtype A6. Bull. Exp. Biol. Med. 2022;172(6):729-733. https://doi.org/10.1007/s10517-022-05466-7
Merkuleva IA, Shcherbakov DN, Borgoyakova MB, Shanshin DV, Rudometov AP, Karpenko LI, Belenkaya SV, Isaeva AA, Nesmeyanova VS, Kazachinskaia EI, Volosnikova EA, Esina TI, Zaykovskaya AV, Pyankov OV, Borisevich SS, Shelemba AA, Chikaev AN, Ilyichev AA. Comparative Immunogenicity of the Recombinant Receptor-Binding Domain of Protein S SARS-CoV-2 Obtained in Prokaryotic and Mammalian Expression Systems. Vaccines (Basel). 2022;10(1):96. https://doi.org/10.3390/vaccines10010096
Sliepen K, Han BW, Bontjer I, Mooij P, Garces F, Behrens AJ, Rantalainen K, Kumar S, Sarkar A, Brouwer PJM, Hua Y, Tolazzi M, Schermer E, Torres JL, Ozorowski G, van der Woude P, de la Peña AT, van Breemen MJ, Camacho-Sánchez JM, Burger JA, Medina-Ramírez M, González N, Alcami J, LaBranche C, Scarlatti G, van Gils MJ, Crispin M, Montefiori DC, Ward AB, Koopman G, Moore JP, Shattock RJ, Bogers WM, Wilson IA, Sanders RW. Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. Nat. Commun. 2019;10(1):2355. https://doi.org/10.1038/s41467-019-10262-5
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 176, No. 7, pp. 112-116, July, 2023
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Rudometova, N.B., Rudometov, A.P., Fando, A.A. et al. Production and Study of Immunochemical Properties of Stabilized Env Trimer of Recombinant Form CRF63_02A6 of HIV-1. Bull Exp Biol Med 176, 96–100 (2023). https://doi.org/10.1007/s10517-023-05978-w
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-023-05978-w